Attention Deficit Hyperactivity Disorder (ADHD) Market Grows with Rising Diagnosis Rates and Novel CNS Therapies | Pfizer Inc., Takeda Pharmaceutical, Novartis AG, Eli Lilly and Company, Lupin

Attention Deficit Hyperactivity Disorder (ADHD) Market size reached US$ 16.23 billion in 2024 and is expected to reach US$ 27.04 billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.

Attention Deficit Hyperactivity Disorder Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With growing mental health awareness, rising ADHD diagnosis rates, and advancements in both stimulant and non-stimulant therapies, the report delivers strategic insights for stakeholders in the neuropsychiatric therapeutics sector from 2025 to 2033.

In 2025, clinical trials in the U.S. are advancing personalized treatment approaches including novel non-stimulant medications, digital therapies, and neurofeedback with improved efficacy and fewer side effects. Additionally, emerging 2025 insights challenge conventional views of ADHD: its symptoms may fluctuate over time, and the long-term efficacy of stimulant medications may diminish after about three years highlighting the need for more nuanced, individualized treatment strategies

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/attention-deficit-hyperactivity-disorder-adhd-market?ophp

The ADHD market includes pharmaceuticals, behavioral therapy programs, and digital health solutions aimed at managing symptoms such as inattention, hyperactivity, and impulsivity. Growth is driven by increasing diagnosis rates, advances in non-stimulant medications, and the integration of telemedicine for behavioral therapy.

Attention Deficit Hyperactivity Disorder Market Competitors Overview:

Pfizer Inc., Takeda Pharmaceutical, Novartis AG, Eli Lilly and Company, Lupin, Mallinckrodt, Hisamitsu Pharmaceutical Co., Inc., Camber Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., and Supernus Pharmaceuticals, Inc., among others.

Important Industry Updates of 2024 and 2025:

In May 2024, Tris Pharma, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved ONYDA XR (clonidine hydrochloride). This once-daily extended-release oral suspension is designed for nighttime dosing and is approved for the treatment of ADHD in pediatric patients aged six and older. It can be used either as a standalone therapy or as an adjunct to approved central nervous system (CNS) stimulant medications.

In March 2025, Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced the successful completion of its Phase III clinical trial for AK0901, a novel investigational drug for the treatment of attention deficit hyperactivity disorder (ADHD). This achievement marks a significant advancement in ArkBio's efforts to develop innovative therapies for pediatric psychiatric conditions and has the potential to provide new and more effective treatment options for children with ADHD in China.

Methodology and Scope

The Attention Deficit Hyperactivity Disorder Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/attention-deficit-hyperactivity-disorder-adhd-market?ophp

Attention Deficit Hyperactivity Disorder Market Segments Overview:

By Type (Predominantly Inattentive Presentation, Predominantly Hyperactive/Impulsive Presentation, Combined Presentation)
By Drug Type (Stimulants, Non-stimulants)
By Age Group (Pediatric, Adults, and Geriatrics)

Regional Overview for Attention Deficit Hyperactivity Disorder Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=attention-deficit-hyperactivity-disorder-adhd-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Attention Deficit Hyperactivity Disorder market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Attention Deficit Hyperactivity Disorder market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.